Search Results
Answer created by AI
- Like
- Disike
AI result is experimental
Generating Answer...
-
Clinical Trials (9966)
-
Therapy Area (2574)
-
Technology (2493)
-
Suvoda WP (2263)
-
Covid-19 (1670)
-
Approvals (1667)
-
Oncology (1666)
-
Drug Development (1621)
-
Infectious Disease (1397)
-
Genomics (1205)
-
API Manufacturers (1131)
-
Foreign Direct Investment (1119)
-
Clinical Trials Arena (801)
-
COVID Cross-sector Impact Brief (530)
-
Country Risk Report Q4 2021 - Professional Services (506)
-
Oracle NAS WP (464)
-
Central Nervous System (435)
-
Neurology (399)
-
Operations (296)
No Filter Selected
-
News Analysis and Comments (18094)
-
Projects (757)
-
Press Releases (660)
-
White Papers (556)
-
Suppliers (281)
-
Supplier Products (105)
No Filter Selected
-
Clinical Trials (59)
-
Contract Research Organization (54)
-
Artificial Intelligence (14)
-
Clinical Data Management Services (14)
-
Consulting (13)
-
Cloud (12)
-
Cybersecurity (12)
-
Bioavailability Studies (11)
-
Clinical Pharmacological Services (11)
-
Clinical Trial Patient Recruitment (11)
-
Environmental, Social, and Governance (11)
-
Internet of Things (11)
-
Analytical Services (10)
-
Biomarker Services (10)
-
Clinical Development Services (10)
-
Clinical Trial Design Services (10)
-
Clinical Trial Monitoring (10)
-
Clinical Trial Site Selection and Management (10)
-
Contract Manufacturers (10)
-
Software & Technology (10)
No Filter Selected
-
United States (4951)
-
Global (1096)
-
United Kingdom (719)
-
North America (694)
-
Europe (579)
-
China (460)
-
United States of America (411)
-
Australia (237)
-
Asia-Pacific (212)
-
Switzerland (190)
-
France (186)
-
Canada (185)
-
UK (184)
-
Japan (168)
-
Germany (142)
-
India (123)
-
Israel (105)
-
US (103)
-
Russia (91)
-
South Korea (72)
No Filter Selected
-
Artificial Intelligence (7)
-
Big Data (5)
-
Biosimilars (1)
-
Blockchain (2)
-
Cell & Gene Therapy (1)
-
Cloud (4)
-
Corporate Governance (4)
-
Covid-19 (4)
-
Cybersecurity (4)
-
Digitalization (2)
-
Easy & Affordable (1)
-
Electronic Medical Record (EMR) Systems (1)
-
Environmental Sustainability (5)
-
Future of Work (3)
-
Genomics (1)
-
Health & Wellness (1)
-
Immuno-oncology (7)
-
Internet of Things (3)
-
Microbiome (2)
-
Mobile Health (1)
No Filter Selected
Boehringer launches Phase IIa trial for diabetic retinopathy
Boehringer Ingelheim has launched a Phase IIa clinical trial (ROBIN) of its product candidate BI 1467335 to treat patients with non-proliferative diabetic retinopathy (NPDR).
Visus concludes subject enrolment in presbyopia therapy trial
The BRIO-I trial enrolled emmetropic phakic and pseudophakic presbyopic participants.
2022 forecast: diabetes, cardiovascular, respiratory trial activity set to rebound
Trial activity is on course to recuperate in hypertension, respiratory tract infections next year.
Amryt’s Oleogel-S10 approvable in epidermolysis bullosa but initial burst of market momentum likely to stall with real-world experience
Amryt Pharma’s Phase III Oleogel-S10 is likely to have swift initial uptake in epidermolysis bullosa (EB) immediately following its anticipated FDA approval, experts said.
Krystal’s dystrophic EB gene therapy trial meets primary goal
VYJUVEK was well-tolerated without any drug-associated serious side effects or discontinuations reported in the trial.
Abeona to initiate Phase III trial of EB-101 to treat RDEB
Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data
In the trial, PTR-01 treatment offered quick, consistent and long-lasting wound healing.
FDA AdCom overwhelmingly supports accelerated approval for Biogen’s tofersen in ALS
AdCom panelists backed an accelerated approval for Biogen’s tofersen in a rare form of ALS based on a new surrogate biomarker.
Plus Therapeutics begins leptomeningeal metastases therapy trial
The trial will assess the single dose of rhenium (186Re) obisbemeda given through an intraventricular catheter in LM patients.
Syneos Health and KX partner for data-driven insights
The collaboration will deliver data-driven predictive analytics, AI and ML capabilities for customers.
AbbVie Parkinson’s drug ABBV-951 faces a few hurdles before FDA approval
ABBV-951’s continuous delivery system of levodopa holds great potential for controlling motor functions.
Coinbase SEC warning shows regulators are coming for crypto
US crypto exchange Coinbase is facing regulatory scrutiny in the wake of financial contagion in the crypto industry – following…
GRIN begins subject dosing in GRIN-related disorders therapy trial
The trial will assess the pharmacokinetics, safety, and effects on seizures, sleep, behavioural symptoms of radiprodil doses.
Enveric chooses Avance Clinical for anxiety disorders therapy trial
The Phase I clinical trial will measure the tolerability and safety of the company’s lead candidate, EB-373.
BridgeBio Pharma starts subject dosing in NSCLC therapy trial
The trial will assess the tolerability, preliminary efficacy, safety, and pharmacodynamics of BBP-398 along with Opdivo.
What would the world look like if we all went on a dopamine detox?
The idea behind the hypothetical detox is that we reset our brains’ reward pathways to become re-accustomed to more a natural level of dopamine release.
Racial disparities in US systemic lupus erythematosus severity
The increase in cases can be attributed to the projected increase in the population.
UK inflation is likely to fall in 2023 (but low-to-zero growth is expected)
The UK narrowly avoided recession in 2022, and the most recent forecasts suggest low and stagnant growth for the near-term…
US companies are tired of “challenging” business with China
US companies are “more negative than they’ve been in a long time” about doing business in China, according to a…
Welfare loss and incentives-based FDI competition
Corporate taxation has implications for international investment allocation. From the global minimum tax debate to the argument for more inclusive…
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286
- 287
- 288
- 289
- 290
- 291
- 292
- 293
- 294
- 295
- 296
- 297
- 298
- 299
- 300
- 301
- 302
- 303
- 304
- 305
- 306
- 307
- 308
- 309
- 310
- 311
- 312
- 313
- 314
- 315
- 316
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342
- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- 357
- 358
- 359
- 360
- 361
- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384
- 385
- 386
- 387
- 388
- 389
- 390
- 391
- 392
- 393
- 394
- 395
- 396
- 397
- 398
- 399
- 400
- 401
- 402
- 403
- 404
- 405
- 406
- 407
- 408
- 409
- 410
- 411
- 412
- 413
- 414
- 415
- 416
- 417
- 418
- 419
- 420
- 421
- 422
- 423
- 424
- 425
- 426
- 427
- 428
- 429
- 430
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443
- 444
- 445
- 446
- 447
- 448
- 449
- 450
- 451
- 452
- 453
- 454
- 455
- 456
- 457
- 458
- 459
- 460
- 461
- 462
- 463
- 464
- 465
- 466
- 467
- 468
- 469
- 470
- 471
- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499
- 500